Review of the prognostic factors in medulloblastoma of children and adults

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 2, 2004, Pages 121-128

  Brandes, Alba A ^a   Paris, Myriam K ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Adult; Chemotherapy; Medulloblastoma; Prognostic factors; Radiotherapy; Review; Toxicity; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; VINCRISTINE;

ADULTHOOD; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; HUMAN; HYDROCEPHALUS; MEDULLOBLASTOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE DISEASE; NEUROSURGERY; PATHOLOGY; PEDIATRICS; PERFORMANCE; POSTOPERATIVE CARE; PROGNOSIS; PSYCHOPATHY; RADIOSURGERY; REVIEW; TREATMENT INDICATION;

ADULT; CEREBELLAR NEOPLASMS; CHILD; HUMANS; MEDULLOBLASTOMA; NEOPLASM STAGING; PROGNOSIS; RECURRENCE;

EID: 2442535265     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.08.005     Document Type: Review

References (69)

1. McNeil D.E., Cote T.R., Clegg L., Rorke L.B. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance epidemiology and end results. Med. Pediatr. Oncol. 39:2002;190-194
2. Brandes A.A., Ermani M., Amistà P. The treatment of adults with medulloblastoma: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 57(3):2003;755-761
3. Newton H.B. Review of the molecular genetics and chemotherapeutic treatment of adult and pediatric medulloblastoma. Expert Opin. Invest. Drugs. 10:2001;2089-2104
4. Chintagumpala M., Berg S., Blaney M.S. Treatment controversies in medulloblastoma. Curr. Opin. Oncol. 13:2001;154-159
5. Kramer J.H., Crowe A.B., Larson D.A., et al. Neuropsychological sequelae of medulloblastoma in adults. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;21-26
6. Carrie C, Lasset C, Lapetite C, et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma: retrospective study of 156 patients. Cancer 1994;2352-60.
7. Peterson K., Walker R.W. Medulloblastoma/PNET in 45 adults. Neurology. 45:1995;440-442
8. Haie-Meder C., Song Y.P. Medulloblastoma: differences in adults and children. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1235-1257
9. Prados M.D., Warnick R.E., Wara M.W., et al. Medulloblastoma in adults. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1145-1152
10. Frost J.P., Laperriere N.J., Wong C.S., et al. Medulloblastoma in adults. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;951-957
11. Sarkar C., Pramanik P., Karak A.K., et al. Are childhood and adult medulloblastoma different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J. Neuroncol. 59:2002;49-61
12. Giordana M.T., Cavallo P., Ditto A., et al. Is medulloblastoma the same tumour in children and adult. J. Neurooncol. 35:1997;169-176
13. Malheiros S.M., Carrete H. Jr., Stavale J.N., et al. MRI of medulloblastoma in adults. Neuroradiology. 45:2003;463-467
14. Kleihues P., Louis D.N., Scheitauer B.W., et al. The WHO classification of tumours of the nervous system. J. Neuropathol. Exp. Neurol. 61:2002;215-225
15. Pomeroy S.L., Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumours outcome based on gene expression. Nature. 415:2002;436-442
16. Wechsler-Reya R., Scott M.P. The developmental biology of brain tumours. Annu. Rev. Neurosci. 24:2001;385-428
17. Brandes A.A., Palmisano V., Monfardini S. Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat. Rev. 25:1999;3-12
18. Rochkind S., Blatt I., Sadeh M., Goldhammer Y. Extracranial metastases of medulloblastoma in adults: a literature review. J. Neurol. Neurosurg. Psychiatry. 54:1991;80-86
19. Brown H.G., Kepner J.L., Perlman E.J., et al. Large-cell/anaplastic medulloblastomas: a pediatric oncology group study. J. Neuropathol. Exp. Neurol. 59:2000;857-865
20. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol. Appl. Neurobiol. 4:2002;257-282
21. Eberhart C.G., Kepner J.L., Goldthwaite P.T., et al. Histopathologic grading of medulloblastoma: a pediatric oncology group study. Cancer. 94:2002;552-560
22. Leonard S.R., Cai D.X., Rivet D.J., et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J. Neurosurg. 95:2001;82-88
23. Giangaspero F., Perilongo G., Fondelli M.P., et al. Medulloblastoma with extensive nodularity: a variant with favourable prognosis. J. Neurosurg. 6:1999;971-977
24. Ildan F., Cetinalp E., Bagdatoglu H., et al. Cerebellar medulloblastoma in adults. Neurosurg. Rev. 17:1994;205-209
25. Malheiros S.M., Franco C.M., Stavale J.N., et al. Medulloblastoma in adults: a series from Brazil. J. Neuroncol. 60:2002;247-253
26. Batra S.K., Mc Lendon R.E., Koo J.S., et al. Prognostic implications of chromosome 17p deletions in human medulloblastoma. J. Neurooncol. 24:1995;39-45
27. Gilbertson R., Wickramasinghe C., Hernan R., et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br. J. Cancer. 85:2001;705-712
28. Biegel J.A., Jans A.J., Raffel C., et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumours (medulloblastomas) of the central nervous system. Clin. Cancer Res. 3:1997;473-478
29. Emadiam S.M., Mc Donald J.D., Gerken J.C., Fults D. Correlations of chromosome 17p loss with clinical outcome in medulloblastoma. Clin. Cancer Res. 2:1996;1559-1564
30. Eberhart C.G., Kratz J.E., Schuster A., et al. Comparative genomic hybridisation detects an increased number of chromosomal alterations in large cell anaplastic medulloblastomas. Brain Pathol. 12:2002;36-44
31. Nicholson J.C., Ross F.M., Kohler J.A., Ellison D.W. Comparative genomic hybridisation and histological variation in primitive neuroectodermal tumours. Br. J. Cancer. 80:1999;1322-1333
32. Scheurlen W.G., Schwabe G.C., Joos S., et al. Molecular analysis of childhood primitive neuroectodermal tumours defines markers associated with poor clinical outcome. J. Clin. Oncol. 16:1998;2478-2485
33. Grotzer M.A., Hogarty M.D., Janss A.J., et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumours/medulloblastoma. Clin. Cancer Res. 7:2001;2425-2433
34. Herms J., Neidt I., Luscher B., et al. C-MYC expression in medulloblastoma and its prognostic value. Int. J. Cancer. 89:2000;395-402
35. Grotzer M.A., Janss A.J., Fung K., et al. TRKC expression predicts good clinical outcome in primitive neuroectodermal tumours. J. Clin. Oncol. 18:2000;2027-2035
36. Albright A.L., Wisoff J.H., Zeltzer P.M., et al. Effects of medulloblastoma resections on outcome in children: a report from the children's cancer group. Neurosurgery. 38:1996;265-271
37. Evans A.E., Jerkin R.D., Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomised trial of radiation therapy with and without CCNU, vincristine and prednisone. J. Neurosurg. 72:1990;572-582
38. Merchant T.E., Wang M.H., Haida T., et al. Medulloblastoma: long term results for patients with definitive radiation therapy during the computed tomography era. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;29-35
39. Yao M.S., Metita M.P., Boyett J.M., et al. The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: a phase III studies in a high-risk population. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;469-476
40. Tait D.M., Thornton Jones H., Bloom H.J., Lemerle J., Morris Jones P. Adjuvant chemotherapy for medulloblastoma. The first multicentre trial of the International Society of Paediatric Oncology SIOP I. Eur. J. Cancer. 26:1990;464-469
41. Zeltzer P.M., Boyett J.M., Finlay J.L., et al. Metastasis stage, adjuvant treatment and residual tumour are prognostic factors for medulloblastoma in children: conclusion from the children's cancer group 921 randomised phase III study. J. Clin. Oncol. 17:1999;832-845
42. Jenkin D., Al Shabanah M.A., Henrik Shail E.A., et al. Prognostic factors for medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;573-584
43. David K.M., Casey A.T., Hayward R.D., et al. Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J. Neurosurg. 86:1997;13-21
44. Chan A.W., Tarbell N.J., Black P.M., et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 47:2000;623-632
45. Le Q.T., Weil M.D., Waro W.M., et al. Adult medulloblastoma: an analysis of survival and prognostic factors. Cancer J. Sci. Am. 3:1997;238-245
46. Cohen B.J., Packer R.J. Chemotherapy for medulloblastomas and primitive neuroectodermal tumours. J. Neurooncol. 29:1996;55-68
47. Kunschner J., Kuttesch J., Hess K., Yung W.K. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Centre experience from 1978 to 1998. Neurooncology. 3:2001;167-173
48. Berger M.S., Baumeister B., Geyer J.R., et al. The risk of metastases from shunting in children with primary central nervous system tumours. J. Neurosurg. 74:1991;872-877
49. Jamjoon Z.A., Jamjoon A.B., Sulaiman A.H., et al. Systemic metastasis of medulloblastoma trough ventriculoperitoneal shunt: report of a case and critical analysis of the literature. Surg. Neurol. 40:1993;403-410
50. Fiorillo A., Maggi G., Martone A., et al. Shunt related abdominal metastases in an infant with medulloblastoma: long term remission by systemic chemotherapy and surgery. J. Neurooncol. 52:2001;273-276
51. Carrasco Torrents R., Sancho M.A., Julia V., et al. Intraabdominal metastasis of cerebellar medulloblastoma trough ventriculoperitoneal shunt. Ann. Esp. Pediatr. 54:2001;83-85
52. Abacioglu U., Uzel O., Sengaz M., Turkan S., Ober A. Medulloblastoma in adults: treatment results and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 54:2002;855-860
53. Paulino A.C., Wen B.C., Mayr N.A., et al. Protracted radiotherapy treatment duration in medulloblastoma. Am. J. Clin. Oncol. 26:2003;55-59
54. Deutsch M., Thomas P.R.M., Krisher J., et al. Results of a prospective randomized trial comparing standard dose neuraxis irradiation [3600 cGy/20] with reduced neuraxis irradiation (2340 cGy/13) in patients with low stage medulloblastoma. A combined children's cancer group pediatric oncology group study. Pediatr. Neurosurg. 24:1996;167-177
55. Thomas P.R., Deutsch M., Kepner J.L., et al. Low- stage medulloblastoma: final analysis of trial comparing standard-dose with reduced dose neuraxis irradiation. J. Clin. Oncol. 18:2000;3004-3011
56. Kun L.E. Medulloblastoma-challenges in radiation therapy and the addition of chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;261-263
57. Mulhern R.K., Kepner J.L., Thomas P.R.M., et al. Neuropsychological functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced (3600 cGy/20 versus 2340 cGy/13) dose craniospinal irradiation. A pediatric oncology group study. J. Clin. Oncol. 16:1998;1723-1728
58. Packer R.J., Golwein J., Nicholson H.S., et al. Treatment of children with medulloblastoma with reduced craniospinal radiation therapy and adjuvant chemotherapy: a children's cancer group study. J. Clin. Oncol. 17:1999;2127-2136
59. Freeman C.R., Taylor R.E., Kortmann R.D., Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research effort. Med. Pediatr. Oncol. 39:2002;99-108
60. Patrice S.J., Tarbell N.J., Goumnerova L.C., et al. Results of radiosurgery in the management of recurrent and residual medulloblastoma. Pediatr. Neurosurg. 22:1995;197-203
61. Woo C., Stea B., Lulu B. The use of stereotactic radiosurgical boost in the treatment of medulloblastomas. Int. J. Radiat. Biol. Phys. 37:1996;761-764
62. Milker-Zabel S., Zabel A., Tilmann C., et al. Results of three-dimensional stereotactically-guided radiotherapy in recurrent medulloblastoma. J. Neurooncol. 60:2002;227-233
63. Gentet J.C., Bouffet E., Doz F., et al. Pre-irradiation chemotherapy including eight drugs in one day regimen and high dose methotrexate in childhood medulloblastoma. Results of the M7 French cooperative study. J. Neurosurg. 82:1998;608-614
64. Heideman R.L., Kovnan E.H., Kelli S.J., et al. Pre-irradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal paediatric CNS tumours. J. Clin. Oncol. 13:1995;2247-2254
65. Hartsell W.F., Guijar A., Heidemann R.L., et al. Patterns of failure in children with medulloblastoma effect of preradiation chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;15-24
66. Bailey C.C., Gnekow A., Wellek S., et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the German Society of Paediatric Oncology (GPO) SIOP II. Med. Pediatr. Oncol. 25:1995;166-178
67. Kortmann R.D., Kuhl J., Timmerman B., et al. Postoperative chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomised trial HIT 91. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;269-279
68. Taylor R.E., Bailey C.C., Robinson K., et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for non-metastatic medulloblastoma. The International Society of Paediatric Oncology/United Kingdom children's cancer study group PNET-3 study. J. Clin. Oncol. 21:2003;1581-1591
69. Zona G., de Tribolet N., Pizzolato G., Dietrich P. Etoposide-carboplatin association as emergency up-front chemotherapy in a case of life-threatening adult medulloblastoma. J. Neurooncol. 39:1998;253-259